PMID- 36794673
OWN - NLM
STAT- MEDLINE
DCOM- 20230510
LR  - 20230511
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 8
DP  - 2023 Apr
TI  - Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint 
      inhibitor-associated neurotoxicity.
PG  - 9373-9383
LID - 10.1002/cam4.5695 [doi]
AB  - BACKGROUND: Oncological patients can benefit substantially from treatment with 
      immune checkpoint inhibitors (ICI). However, there is a growing awareness of 
      immune-related adverse events (irAE). Especially ICI-mediated neurological 
      adverse events (nAE(+)), are tough to diagnose and biomarkers to identify 
      patients at risk are missing. METHODS: A prospective register with prespecified 
      examinations was established for ICI treated patients in December 2019. At the 
      time of data cut-off, 110 patients were enrolled and completed the clinical 
      protocol. Herein, cytokines and serum neurofilament light chain (sNFL) from 21 
      patients were analyzed. RESULTS: nAE of any grade were observed in 31% of the 
      patients (n = 34/110). In nAE(+) patients a significant increase in sNFL 
      concentrations over time was observed. Patients with higher-grade nAE had 
      significantly elevated serum-concentrations of monocyte chemoattractant protein 1 
      (MCP-1) and brain-derived neurotrophic factor (BDNF) at baseline compared to 
      individuals without any nAE (p < 0.01 and p < 0.05). CONCLUSION: Here, we 
      identified nAE to occur more frequently than previously reported. Increase of 
      sNFL during nAE confirms the clinical diagnosis of neurotoxicity and might be a 
      suitable marker for neuronal damage associated with ICI therapy. Furthermore, 
      MCP-1 and BDNF are potentially the first clinical-class nAE predictors for 
      patients under ICI therapy.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Mohn, Nora
AU  - Mohn N
AUID- ORCID: 0000-0002-9102-124X
AD  - Department of Neurology, Hannover Medical School, Hannover, Germany.
FAU - Mahjoub, Susann
AU  - Mahjoub S
AD  - Department of Neurology, Hannover Medical School, Hannover, Germany.
FAU - Duzzi, Laura
AU  - Duzzi L
AD  - Department of Neurology, Hannover Medical School, Hannover, Germany.
FAU - Narten, Emily
AU  - Narten E
AD  - Department of Neurology, Hannover Medical School, Hannover, Germany.
FAU - Grote-Levi, Lea
AU  - Grote-Levi L
AD  - Department of Neurology, Hannover Medical School, Hannover, Germany.
FAU - Korner, Gudrun
AU  - Korner G
AD  - Department of Neurology, Hannover Medical School, Hannover, Germany.
FAU - Seeliger, Tabea
AU  - Seeliger T
AD  - Department of Neurology, Hannover Medical School, Hannover, Germany.
FAU - Beutel, Gernot
AU  - Beutel G
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, 
      Hannover Medical School, Hannover, Germany.
FAU - Bollmann, Benjamin-Alexander
AU  - Bollmann BA
AD  - Department of Pneumology, Hannover Medical School, Hannover, Germany.
FAU - Wirth, Thomas
AU  - Wirth T
AD  - Department of Gastroenterology, Hannover Medical School, Hannover, Germany.
FAU - Huss, Andre
AU  - Huss A
AD  - Department of Neurology, University Hospital Ulm, Ulm, Germany.
FAU - Tumani, Hayrettin
AU  - Tumani H
AD  - Department of Neurology, University Hospital Ulm, Ulm, Germany.
FAU - Grimmelmann, Imke
AU  - Grimmelmann I
AD  - Skin-Cancer-Center, Hannover Medical School, Hannover, Germany.
FAU - Gutzmer, Ralf
AU  - Gutzmer R
AD  - Skin-Cancer-Center, Hannover Medical School, Hannover, Germany.
AD  - Department of Dermatology Venerology, Allergy and Phlebology, Hannover Medical 
      School, Minden, Germany.
FAU - Ivanyi, Philipp
AU  - Ivanyi P
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, 
      Hannover Medical School, Hannover, Germany.
FAU - Skripuletz, Thomas
AU  - Skripuletz T
AD  - Department of Neurology, Hannover Medical School, Hannover, Germany.
CN  - ICOG-CCCH (Immune Cooperative Oncology Group; Comprehensive Cancer Center 
      Hannover)
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230216
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
SB  - IM
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/adverse effects
MH  - *Brain-Derived Neurotrophic Factor
MH  - Chemokine CCL2
MH  - Biomarkers
MH  - Cytokines
PMC - PMC10166892
OTO - NOTNLM
OT  - biomarker
OT  - immune-related adverse events
OT  - immunotherapy
OT  - neurotoxicity
OT  - serum neurofilament light chains
COIS- All authors declare that they have no competing financial interests or personal 
      relationships that could have appeared to influence the work reported in this 
      paper.
EDAT- 2023/02/17 06:00
MHDA- 2023/05/10 06:42
PMCR- 2023/02/16
CRDT- 2023/02/16 05:52
PHST- 2023/01/25 00:00 [revised]
PHST- 2022/11/29 00:00 [received]
PHST- 2023/02/02 00:00 [accepted]
PHST- 2023/05/10 06:42 [medline]
PHST- 2023/02/17 06:00 [pubmed]
PHST- 2023/02/16 05:52 [entrez]
PHST- 2023/02/16 00:00 [pmc-release]
AID - CAM45695 [pii]
AID - 10.1002/cam4.5695 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Apr;12(8):9373-9383. doi: 10.1002/cam4.5695. Epub 2023 Feb 16.